Related Experiment Video
Updated: May 12, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Continuous subcutaneous insulin infusion: practical issues
Banshi D Saboo1, Praful A Talaviya
1Dia Care, Diabetes care and Hormone Clinic, Ahmedabad, Gujarat, India.
Indian Journal of Endocrinology and Metabolism
|April 9, 2013
Summary
Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, improves quality of life for diabetes mellitus patients. Careful patient selection and management are crucial to avoid adverse events like hyperglycemia or hypoglycemia.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Medical Devices
Background:
- Diabetes mellitus prevalence is rising globally.
- Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is an intensive treatment option.
- CSII offers improved quality of life and treatment satisfaction for patients with diabetes mellitus.
Purpose of the Study:
- To review practical aspects of insulin pump therapy.
- To identify and address challenges in CSII implementation.
- To guide clinicians in selecting appropriate candidates and managing potential adverse reactions.
Main Methods:
- Literature review of studies on insulin pump therapy.
- Analysis of practical considerations for CSII use.
- Exploration of user-related errors and adverse events.
Main Results:
- Insulin pump therapy can enhance patient quality of life.
- Manual errors in CSII use may lead to hypo- or hyperglycemia, potentially causing diabetic ketoacidosis (DKA).
- Key practical aspects include candidate selection, device handling, site selection, and pump settings.
Conclusions:
- Insulin pump therapy is a valuable tool for intensive diabetes management.
- Thorough candidate assessment and user education are essential for safe and effective CSII.
- Addressing practical challenges can optimize outcomes and minimize risks associated with insulin pump therapy.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
01:28IV Infusion to Oral Dosing: Conversion Methods
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...